Novartis Reports Weaker-Than-Expected Q1 Results Amid Generic Competition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 28 2026
0mins
Should l Buy NVS?
Source: seekingalpha
- Sales Decline: Novartis reported Q1 net sales of $13.1 billion, a 1% year-over-year decline and a 5% drop in constant currency, primarily due to 14 percentage points of generic competition offsetting 13 percentage points of volume growth, indicating significant market pressure.
- Core Profit Drop: Core operating profit fell to $4.9 billion, down 12% year-over-year and below the $5.18 billion forecast by analysts, reflecting the negative impact of declining net sales and increased R&D investments on profitability.
- Patent Cliff Challenge: Facing the steepest patent cliff in its history, Novartis saw a 42% drop in sales of its key drug Entresto, posing a significant revenue threat, although demand for newer therapies like Kisqali and Pluvicto surged by 59% and 73%, respectively, providing some support for future growth.
- Full-Year Outlook: Despite challenges, Novartis remains on track for low single-digit sales growth and a low single-digit decline in core operating income for 2026, with the CEO expressing optimism about multiple drug readouts in the second half that could enhance mid- to long-term growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVS
Wall Street analysts forecast NVS stock price to fall
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 145.390
Low
112.00
Averages
127.75
High
143.00
Current: 145.390
Low
112.00
Averages
127.75
High
143.00
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novartis to Close Wehr Facility by End of 2028
- Production Strategy Shift: Novartis plans to close its Wehr manufacturing site by the end of 2028, which primarily produces solid oral dosage forms, due to its lack of competitiveness, resulting in an expected reduction of around 220 jobs, marking a significant shift in the company's production strategy.
- Commitment to Transparency: Novartis emphasizes a responsible and transparent approach in communicating with employee representatives through Germany's legally required information and consultation procedures, acknowledging the uncertainty this decision creates for employees and the local community.
- Ongoing Investment Commitment: Despite the closure of the Wehr facility, Novartis reaffirms its commitment to the German market by continuing investments in research, development, and clinical studies, ensuring that the supply of medicines to patients remains unaffected.
- Investment in Innovative Manufacturing: Novartis has announced a €35 million investment in a new radioligand therapy production facility in Halle, expected to begin operations in 2027, aimed at providing personalized cancer therapies for patients in Germany, reflecting the company's strategic push towards innovative manufacturing technologies.
See More
German Stock Market Hit Hard by New COVID Variant Concerns
- Market Reaction: The German stock market has faced a significant blow due to concerns over a new COVID variant emerging in South Africa, leading to a sharp decline in major indices and reflecting investor anxiety about a potential resurgence of the pandemic.
- Holiday Impact: With most global stock markets closed for Labor Day, trading volumes have plummeted, particularly in Asia where markets in Hong Kong and the mainland remained shut, exacerbating market uncertainty.
- Economic Outlook: Despite the European Central Bank and Bank of England holding rates steady, expectations for future rate hikes have risen, with traders pricing in a 75% chance of an ECB hike in June, which could impact investor confidence moving forward.
- Industry Dynamics: In the U.S., Apple has issued a better-than-expected revenue forecast, showcasing strong sales and earnings, which may positively influence global markets, particularly in the tech sector.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
Market Volatility Amidst Surging Oil Prices
- Surging Oil Prices: Brent crude has reached wartime highs, raising investor concerns about the potential resumption of armed conflict, which could negatively impact global economic recovery and market stability.
- Market Decline: Asian markets are down across the board, with futures indicating similar losses in the U.S. and Europe, despite the S&P 500 being on track for its best month since 2020, highlighting market fragility amidst volatility.
- Central Bank Policies: The Bank of England and European Central Bank are set to announce interest rate decisions today, with economists predicting both will hold rates steady at 3.75% and 2% respectively, in response to inflationary pressures and uncertainty.
- Corporate Earnings: Major banks including Standard Chartered, BNP Paribas, and Societe Generale have all exceeded profit expectations, demonstrating resilience in the financial sector that may provide support for the broader market.
See More
AstraZeneca and GSK Q1 Earnings Beat Expectations
- AstraZeneca Earnings Surprise: AstraZeneca reported a core earnings per share of $2.58 for Q1, surpassing the expected $2.53, indicating strong performance in a competitive pharmaceutical market, which is likely to boost investor confidence further.
- GSK's Strong Performance: GSK's core EPS was £0.47 ($0.63), exceeding the forecast of £0.43, reflecting success in new drug development and market penetration, which may attract more investor interest in its growth potential.
- Market Environment Challenges: As President Trump pushes for lower drug prices in the U.S., pharma CEOs warn that Europe could see fewer new drug launches unless competitiveness issues are addressed, potentially impacting AstraZeneca and GSK's long-term strategic plans.
- Revenue Growth Momentum: AstraZeneca's Q1 revenue reached $15.3 billion, an 8% year-on-year increase, beating expectations of $14.9 billion, indicating a strong start towards its goal of $80 billion in revenue by 2030, while GSK also reported revenue of £7.63 billion, up 5%.
See More
UAE's OPEC Exit Sends Shockwaves Through Markets
- UAE Exits OPEC: The UAE announced its exit from OPEC effective May 1, with the Energy Minister stating a desire for more freedom to achieve a capacity goal of 5 million barrels per day by 2027, a move that could prompt other members to follow suit and weaken OPEC's influence.
- Muted Market Reaction: Despite the significant news of the UAE's departure, oil prices remain stable, and both Asian stocks and European futures show relatively muted performance, indicating a cautious market response to the announcement.
- Strong European Banking Performance: UBS reported a first-quarter profit of $3 billion, exceeding expectations, while Santander's profit surged by 60%, and Deutsche Bank also beat bottom-line forecasts, highlighting a robust recovery in the European banking sector.
- Airline Industry Crisis Warning: Ryanair's CEO warned that European airlines could face bankruptcy if jet fuel prices do not decline, reflecting the industry's concerns over rising operational costs.
See More
Novartis to Close Wehr Facility by End of 2028
- Production Strategy Shift: Novartis plans to close its Wehr manufacturing site by the end of 2028, which primarily produces solid oral dosage forms, due to its lack of competitiveness, resulting in an expected reduction of around 220 jobs, marking a significant shift in the company's production strategy.
- Commitment to Transparency: Novartis emphasizes a responsible and transparent approach in communicating with employee representatives through Germany's legally required information and consultation procedures, acknowledging the uncertainty this decision creates for employees and the local community.
- Ongoing Investment Commitment: Despite the closure of the Wehr facility, Novartis reaffirms its commitment to the German market by continuing investments in research, development, and clinical studies, ensuring that the supply of medicines to patients remains unaffected.
- Investment in Innovative Manufacturing: Novartis has announced a €35 million investment in a new radioligand therapy production facility in Halle, expected to begin operations in 2027, aimed at providing personalized cancer therapies for patients in Germany, reflecting the company's strategic push towards innovative manufacturing technologies.
See More
German Stock Market Hit Hard by New COVID Variant Concerns
- Market Reaction: The German stock market has faced a significant blow due to concerns over a new COVID variant emerging in South Africa, leading to a sharp decline in major indices and reflecting investor anxiety about a potential resurgence of the pandemic.
- Holiday Impact: With most global stock markets closed for Labor Day, trading volumes have plummeted, particularly in Asia where markets in Hong Kong and the mainland remained shut, exacerbating market uncertainty.
- Economic Outlook: Despite the European Central Bank and Bank of England holding rates steady, expectations for future rate hikes have risen, with traders pricing in a 75% chance of an ECB hike in June, which could impact investor confidence moving forward.
- Industry Dynamics: In the U.S., Apple has issued a better-than-expected revenue forecast, showcasing strong sales and earnings, which may positively influence global markets, particularly in the tech sector.
See More
Latest Developments in the Biotech Sector
- Regulatory Approvals: Crinetics received European Commission approval for PALSONIFY to treat acromegaly in adults, becoming the first once-daily oral therapy in Europe, covering 27 EU member states, which is expected to significantly enhance market share.
- Acquisition Expansion: Teva is acquiring Emalex Biosciences for $700 million, bolstering its neuroscience pipeline and potentially accelerating the NDA submission for Ecopipam, thereby strengthening Teva's competitive position in the CNS disorders market.
- Clinical Trial Progress: Biomea Fusion's Icovamenib showed a 52% increase in mean C-peptide AUC in its Phase 2 trial for Type 1 Diabetes, indicating potential efficacy in early-stage patients, which may drive further development efforts.
- Market Reactions: Despite multiple approvals, AstraZeneca and Novartis saw their stock prices decline by 0.79% and 1.76% respectively, reflecting a cautious investor sentiment towards the biotech sector.
See More
Market Volatility Amidst Surging Oil Prices
- Surging Oil Prices: Brent crude has reached wartime highs, raising investor concerns about the potential resumption of armed conflict, which could negatively impact global economic recovery and market stability.
- Market Decline: Asian markets are down across the board, with futures indicating similar losses in the U.S. and Europe, despite the S&P 500 being on track for its best month since 2020, highlighting market fragility amidst volatility.
- Central Bank Policies: The Bank of England and European Central Bank are set to announce interest rate decisions today, with economists predicting both will hold rates steady at 3.75% and 2% respectively, in response to inflationary pressures and uncertainty.
- Corporate Earnings: Major banks including Standard Chartered, BNP Paribas, and Societe Generale have all exceeded profit expectations, demonstrating resilience in the financial sector that may provide support for the broader market.
See More
AstraZeneca and GSK Q1 Earnings Beat Expectations
- AstraZeneca Earnings Surprise: AstraZeneca reported a core earnings per share of $2.58 for Q1, surpassing the expected $2.53, indicating strong performance in a competitive pharmaceutical market, which is likely to boost investor confidence further.
- GSK's Strong Performance: GSK's core EPS was £0.47 ($0.63), exceeding the forecast of £0.43, reflecting success in new drug development and market penetration, which may attract more investor interest in its growth potential.
- Market Environment Challenges: As President Trump pushes for lower drug prices in the U.S., pharma CEOs warn that Europe could see fewer new drug launches unless competitiveness issues are addressed, potentially impacting AstraZeneca and GSK's long-term strategic plans.
- Revenue Growth Momentum: AstraZeneca's Q1 revenue reached $15.3 billion, an 8% year-on-year increase, beating expectations of $14.9 billion, indicating a strong start towards its goal of $80 billion in revenue by 2030, while GSK also reported revenue of £7.63 billion, up 5%.
See More
UAE's OPEC Exit Sends Shockwaves Through Markets
- UAE Exits OPEC: The UAE announced its exit from OPEC effective May 1, with the Energy Minister stating a desire for more freedom to achieve a capacity goal of 5 million barrels per day by 2027, a move that could prompt other members to follow suit and weaken OPEC's influence.
- Muted Market Reaction: Despite the significant news of the UAE's departure, oil prices remain stable, and both Asian stocks and European futures show relatively muted performance, indicating a cautious market response to the announcement.
- Strong European Banking Performance: UBS reported a first-quarter profit of $3 billion, exceeding expectations, while Santander's profit surged by 60%, and Deutsche Bank also beat bottom-line forecasts, highlighting a robust recovery in the European banking sector.
- Airline Industry Crisis Warning: Ryanair's CEO warned that European airlines could face bankruptcy if jet fuel prices do not decline, reflecting the industry's concerns over rising operational costs.
See More
